Suven Life Sciences

Suven, Inc. a Delaware company, a wholly owned subsidiary of Suven Life Sciences Limited, India, is a clinical-stage biopharmaceutical company focused on acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Suven Life Sciences' discovery research programs are focused on discovering and developing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets, having world wide patents. Suven has 3 clinical stage compounds, a Phase 2 initiated candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 initiated candidate SUVN-D-4010 for Alzheimer's disease and Schizophrenia. In addition, the Company has Ten (10) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.